Research and Markets: Atrial Fibrillation - Pipeline Review Report, H2 2014 - 15 Companies & 27 Drug Profiles

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/drhq9t/atrial) has announced the addition of the "Atrial Fibrillation - Pipeline Review, H2 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Isis Pharmaceuticals, Inc.
  • Gilead Sciences, Inc.
  • Daiichi Sankyo Company, Limited
  • Nissan Chemical Industries, Ltd.
  • Laboratoires Pierre Fabre SA
  • Cardiome Pharma Corp
  • Xention Limited
  • HUYA Bioscience International, LLC
  • Milestone Pharmaceuticals, Inc.
  • Otsuka Holdings Co., Ltd.
  • Serodus ASA
  • Nyken BV
  • Armetheon, Inc.

Drug Profiles

  • edoxaban tosylate
  • tecarfarin
  • vernakalant hydrochloride
  • bucindolol hydrochloride
  • vernakalant hydrochloride
  • ranolazine ER
  • XEN-D0103
  • HBI-3000
  • ISIS-CRPRx
  • (ranolazine + dronedarone)
  • vanoxerine
  • F-373280
  • BMS-919373
  • XEN-D0101
  • OPC-108459
  • budiodarone
  • Small Molecule to Inhibit IKACh for Atrial Fibrillation
  • MSP-2017
  • NYK-1112
  • SER-102
  • XEN-R0702
  • GsMTx-4
  • NIP-151
  • Small Molecule to Block Kv1.5 for Atrial Fibrillation
  • Drug For Atrial Fibrillation
  • Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation
  • Small Molecules to Inhibit Voltage Gated Sodium Channel for Atrial Fibrillation

For more information visit http://www.researchandmarkets.com/research/drhq9t/atrial

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular